Trials / Withdrawn
WithdrawnNCT04878315
Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions
An Open-label, Randomized Three Period, Three Sequence, Partially Replicated Crossover Bioequivalence Study of Two Oral Formulations of Captopril 50 mg Film Coated Tablets in Healthy Adult Participants Under Fasting Conditions
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a bioequivalence study to compare Capoten (test product \[T\]) versus captopril (reference product \[R\]) produced by Mylan Pharmaceuticals Spain, in healthy adult participants under fasting condition. Capoten is the registered trademark of SmithKline Beecham Egypt.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capoten | Capoten will be administered per the treatment sequence |
| DRUG | Captopril | Captopril will be administered per the treatment sequence |
Timeline
- Start date
- 2022-02-13
- Primary completion
- 2022-03-25
- Completion
- 2022-03-25
- First posted
- 2021-05-07
- Last updated
- 2023-01-27
Source: ClinicalTrials.gov record NCT04878315. Inclusion in this directory is not an endorsement.